Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test
Cardiff Universityn = 165Sept 2008 to 31 Jan 2013
Healthy · Adrenal Insufficiency · Hypopituitarism
PepBank has 57 cosyntropin studies with results. 28 of them gave cosyntropin, with 97 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 97 results and 992 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Cosyntropin, or tetracosactide, matches the first 24 residues of ACTH. The cited US label uses it as a diagnostic agent for adrenocortical insufficiency.
| Target | Action | Evidence |
|---|---|---|
| Melanocortin 2 receptorMC2RQ01718 (opens in a new tab) | Agonist | Open Targets mechanism table, curated from ChEMBLSource (opens in a new tab) |
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
24 amino acids
Calculated from the two sequences. Curated notes are shown as given.
24 of 24 aligned residues identical (100%) · Corticotropin 1–24
No differences in the aligned region.
Basis: UniProt P01189 places mature human corticotropin at residues 138-176. Cosyntropin equals precursor residues 138-161 and mature corticotropin residues 1-24. This parent denotes the pure sequence, not the Acthar mixture.
Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
pI 11.26 · Net charge at pH 7.4: 6.05
Point or use arrow keys
Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.
| pH | Net charge |
|---|---|
| 0 | 9.00 |
| 1 | 9.00 |
| 2 | 8.97 |
| 3 | 8.73 |
| 4 | 7.84 |
| 5 | 7.12 |
| 6 | 6.77 |
| 7 | 6.22 |
| 8 | 5.81 |
| 9 | 5.08 |
| 10 | 3.60 |
| 11 | 0.68 |
| 12 | −1.46 |
| 13 | −3.25 |
| 14 | −3.91 |
24 residues. Each residue counts in one class; F and W count as aromatic.
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).
Cosyntropin has 24 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.
SMILES fromPubChem CID 16133751(opens in a new tab)
CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CO)NAn ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.
Eisenberg consensus (normalized) scale · + K, R · − D, E
Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.
| Position | Residue | Angle | Eisenberg consensus (normalized) |
|---|---|---|---|
| 1 | S | 0° | -0.18 |
| 2 | Y | 100° | 0.26 |
| 3 | S | 200° | -0.18 |
| 4 | M | 300° | 0.64 |
| 5 | E | 40° | -0.74 |
| 6 | H | 140° | -0.40 |
| 7 | F | 240° | 1.19 |
| 8 | R | 340° | -2.53 |
| 9 | W | 80° | 0.81 |
| 10 | G | 180° | 0.48 |
| 11 | K | 280° | -1.50 |
| 12 | P | 20° | 0.12 |
| 13 | V | 120° | 1.08 |
| 14 | G | 220° | 0.48 |
| 15 | K | 320° | -1.50 |
| 16 | K | 60° | -1.50 |
| 17 | R | 160° | -2.53 |
| 18 | R | 260° | -2.53 |
| 19 | P | 0° | 0.12 |
| 20 | V | 100° | 1.08 |
| 21 | K | 200° | -1.50 |
| 22 | V | 300° | 1.08 |
| 23 | Y | 40° | 0.26 |
| 24 | P | 140° | 0.12 |
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Cosyntropin has 992 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.
Studies by year
57 of 992 studies have results (5.7%), published 1968 to 2025. Top row: every study. Bottom row: studies with results about Cosyntropin, by class. The rows use different scales.
Studies991 in all, 1968 to 2026
Studies with results57 in all, 1968 to 2025
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
27 trials match. Highest phase first. Data from ClinicalTrials.gov.
25 of 27 trials
Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation
NCT0142179710 Oct 2006 to est. Dec 2024
Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test
NCT00851942Sept 2008 to 31 Jan 2013
Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery
NCT01839812Mar 2009 to Jun 2013
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
NCT00989781Sept 2009 to Sept 2013
The Adrenal Contribution to Androgen Production in Girls During Puberty
NCT01062568Feb 2010 to Jul 2014
Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures
NCT01673087Oct 2012 to 15 Aug 2017
25 trials · 4 ongoing · 14 completed · 5 stopped early · 7 with posted results · source ClinicalTrials.gov (opens in a new tab)
Cardiff Universityn = 165Sept 2008 to 31 Jan 2013
Healthy · Adrenal Insufficiency · Hypopituitarism
Johns Hopkins Universityn = 0est. Jul 2019 to est. 31 Dec 2020
Adrenal Insufficiency
United States Naval Medical Center, San Diegon = 29Aug 2010 to Apr 2014
Postdural Puncture Headache
Newcastle Universityn = 13Sept 2010 to Sept 2012
Adrenal Failure
University of Virginian = 10029 Jan 2018 to 12 Mar 2019
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia · Lecithin Acyltransferase Deficiency
University of Colorado, Denvern = 39419 Apr 2018 to est. Aug 2021
Infantile Spasm
University of California, San Diegon = 50Feb 2010 to Jul 2014
Development
Hospices Civils de Lyonn = 46Oct 2016 to 21 Nov 2022
Post-dural Puncture Headache
Sheffield Children's NHS Foundation Trustn = 1212 Oct 2012 to est. 1 Dec 2025
Adrenal Suppression
Mallinckrodt ARD LLCn = 4427 Jul 2018 to 25 Feb 2020
Muscular Dystrophy, Duchenne
Radboud University Medical Centern = 20Jul 2008 to Dec 2012
Idiopathic Membranous Nephropathy
Peter y. Liun = 808 May 2017 to est. 30 Jun 2026
Sleep Restriction
University of Michigann = 256Oct 2012 to 15 Aug 2017
Stress
Mayo Clinicn = 35Mar 2009 to Jun 2013
Adrenal Cortex Diseases · Infant Morbidity
Benjamin Vigliantin = 241 Nov 2021 to est. Dec 2026
Radiotracer · Hypertension · Cholesterol
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Centern = 59 Feb 2020 to est. 24 Jun 2026
Sleep Restriction
University of Virginian = 1448 Oct 2019 to est. 1 May 2026
Polycystic Ovary Syndrome
Nationwide Children's Hospitaln = 101 Oct 2017 to 31 Jan 2019
Adrenal Insufficiency · Osteopenia, Osteoporosis · Steroid Suppression of ACTH Secretion
University of Virginian = 01 Jun 2018 to 17 Jul 2018
Hyperandrogenemia · Obesity · Polycystic Ovary Syndrome
Brigham and Women's Hospitaln = 23Apr 2015 to Nov 2020
Autonomic Nervous System · Baroreflex · Stress, Physiological
University of Virginian = 762 Aug 2021 to 30 Jun 2024
Cirrhosis · Adrenal Insufficiency
Haukeland University Hospitaln = 23221 May 2016 to 21 Dec 2017
Adrenal Insufficiency
University of Virginian = 8410 Oct 2006 to est. Dec 2024
Hyperandrogenemia · Polycystic Ovary Syndrome · Obesity
Vanderbilt Universityn = 13Jan 2013 to 31 Dec 2020
Postural Tachycardia Syndrome
University of California, San Diegon = 41Sept 2009 to Sept 2013
Polycystic Ovary Syndrome
13 more mention it but do not test it. They are not trials of Cosyntropin: they only measure it (a blood level or an eligibility term) or name it in their text.
Studies on this peptide. Some have results. The others have none yet.
992 studies match. Retracted studies are left out.
Showing 25 of 992 studiesquery qry_47c121eeabfdc5bf98eeab59
57 studies in all, 2 on this page
Non-randomized trial · 2004
Lux et al. 2004Lancet (London, England)n = 25cited by 264
PMID 15541450DOI 10.1016/s0140-6736(04)17400-xPUB-15541450
Not a test of Cosyntropin alone · 1999
Abdu et al. 1999The Journal of clinical endocrinology and metabolismcited by 198
PMID 10084558DOI 10.1210/jcem.84.3.5535PUB-10084558
926 studies in all, 23 on this page
PubMed tag: none · 2000
Annane et al. 2000JAMAcited by 646
PMID 10697064DOI 10.1001/jama.283.8.1038PUB-10697064
PubMed tag: none · 2004
Hamrahian et al. 2004The New England journal of medicinecited by 437
PMID 15084695DOI 10.1056/nejmoa020266PUB-15084695
PubMed tag: Clinical Trial, Multicenter Study · 2012
Rossi et al. 2012The Journal of clinical endocrinology and metabolismcited by 281
PMID 22399502DOI 10.1210/jc.2011-2830PUB-22399502
PubMed tag: none · 2001
Lieberman et al. 2001The Journal of clinical endocrinology and metabolismcited by 243
PMID 11397882DOI 10.1210/jcem.86.6.7592PUB-11397882
PubMed tag: Randomized Controlled Trial, Multicenter Study · 2017
O'Callaghan et al. 2017The Lancet. Neurologycited by 221
PMID 27838190DOI 10.1016/s1474-4422(16)30294-0PUB-27838190
PubMed tag: Randomized Controlled Trial, Clinical Trial · 1998
Thomsen et al. 1998The New England journal of medicinecited by 211
PMID 9691103DOI 10.1056/nejm199808063390603PUB-09691103
PubMed tag: none · 2006
Annane et al. 2006American journal of respiratory and critical care medicinecited by 211
PMID 16973979DOI 10.1164/rccm.200509-1369ocPUB-16973979
PubMed tag: Clinical Trial, Comparative Study · 2006
Ho et al. 2006The Journal of clinical endocrinology and metabolismcited by 199
PMID 16263835DOI 10.1210/jc.2005-0265PUB-16263835
PubMed tag: none · 2017
Annane et al. 2017Critical care medicinecited by 194
PMID 28938253DOI 10.1097/ccm.0000000000002737PUB-28938253
PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase III · 2000
Schenkel et al. 2000Pediatricscited by 190
PMID 10654982DOI 10.1542/peds.105.2.e22PUB-10654982
PubMed tag: none · 2022
Yip et al. 2022JAMA surgerycited by 180
PMID 35976622PMC9386598DOI 10.1001/jamasurg.2022.3544PUB-35976622
PubMed tag: none · 2016
Turcu et al. 2016European journal of endocrinologycited by 179
PMID 26865584PMC4874183DOI 10.1530/eje-15-1181PUB-26865584
PubMed tag: Randomized Controlled Trial, Clinical Trial · 2000
Skoner et al. 2000Pediatricscited by 177
PMID 10654983DOI 10.1542/peds.105.2.e23PUB-10654983
PubMed tag: none · 2004
Kivity et al. 2004Epilepsiacited by 151
PMID 15009227DOI 10.1111/j.0013-9580.2004.30503.xPUB-15009227
PubMed tag: none · 2015
Peitzsch et al. 2015The Journal of steroid biochemistry and molecular biologycited by 138
PMID 25312486DOI 10.1016/j.jsbmb.2014.10.006PUB-25312486
PubMed tag: none · 2005
Marik et al. 2005Critical care medicinecited by 135
PMID 15942340PMC2989684DOI 10.1097/01.ccm.0000164541.12106.57PUB-15942340
PubMed tag: Randomized Controlled Trial, Comparative Study · 2018
O'Callaghan et al. 2018The Lancet. Child & adolescent healthcited by 130
PMID 30236380DOI 10.1016/s2352-4642(18)30244-xPUB-30236380
PubMed tag: Randomized Controlled Trial, Clinical Trial · 1998
McKenzie et al. 1998JAMAcited by 124
PMID 9757853DOI 10.1001/jama.280.12.1061PUB-09757853
PubMed tag: none · 1987
Jurney et al. 1987Chestcited by 122
PMID 3038477DOI 10.1378/chest.92.2.292PUB-03038477
PubMed tag: none · 1987
Membreno et al. 1987The Journal of clinical endocrinology and metabolismcited by 120
PMID 3040796DOI 10.1210/jcem-65-3-482PUB-03040796
PubMed tag: none · 1995
Rubin et al. 1995Archives of general psychiatrycited by 119
PMID 7872849DOI 10.1001/archpsyc.1995.03950150045009PUB-07872849
PubMed tag: none · 2021
Javorsky et al. 2021Journal of the Endocrine Societycited by 119
PMID 33768189PMC7975762DOI 10.1210/jendso/bvab022PUB-33768189
PubMed tag: Randomized Controlled Trial, Clinical Trial · 1998
Busse et al. 1998The Journal of allergy and clinical immunologycited by 117
PMID 9564797DOI 10.1016/s0091-6749(98)70353-7PUB-09564797
Page 1 of 2
Osborne JP · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · 2023
Randomized controlled trial · 4 results
Dziadzko M · British journal of anaesthesia · 2025
Randomized controlled trial · 7 results
Knupp KG · Journal of child neurology · 2022
Randomized controlled trial · 1 result
Brice P · Bulletin du cancer · 1989
Randomized controlled trial · 3 results
Noera G · Military Medical Research · 2024
Randomized controlled trial · 3 results
Bonneterre J · European journal of cancer (Oxford, England : 1990) · 1991
Randomized controlled trial · 5 results
Hakim SM · Anesthesiology · 2010
Randomized controlled trial · 5 results
Orandi AH · Rheumatology advances in practice · 2025
Randomized controlled trial · 4 results
Hanling SR · Pain medicine (Malden, Mass.) · 2016
Randomized controlled trial · 8 results
Zaheer S · Endocrine connections · 2021
Randomized controlled trial · 2 results
Zeger W · World journal of emergency medicine · 2012
Randomized controlled trial · 2 results
Leung JH · The Journal of clinical endocrinology and metabolism · 2020
Randomized controlled trial · 5 results
Lux AL · Lancet (London, England) · 2004
Non-randomized trial · 2 results
Culine S · Bulletin du cancer · 1989
Non-randomized trial · 2 results
Duran F · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 1975
Non-randomized trial · 1 result
el-Shaboury AH · British medical journal · 1968
Non-randomized trial · 4 results
Treadwell BL · British medical journal · 1969
Non-randomized trial · 2 results
Heksch R · Annals of pediatric endocrinology & metabolism · 2021
Non-randomized trial · 2 results
Seely EW · The Journal of clinical endocrinology and metabolism · 1989
Non-randomized trial · 5 results
Kennedy AC · Annals of the rheumatic diseases · 1979
Non-randomized trial · 1 result
Collins JV · The Quarterly journal of medicine · 1975
Observational study · 2 results
Vergoni AV · Neuropeptides · 1986
Animal study (in vivo) · rat · 2 results
Wooding FB · Journal of reproduction and fertility · 1986
Animal study (in vivo) · sheep and goats · 2 results
Tetel V · General and comparative endocrinology · 2022
Animal study (in vivo) · anas platyrhynchos domesticus · 3 results
Kertmen H · Archives of medical science : AMS · 2018
Animal study (in vivo) · rabbit · 9 results
Rossdale PD · Journal of reproduction and fertility. Supplement · 1982
Animal study (in vivo) · horse · 6 results
Wüthrich P · Pharmaceutical research · 1994
Animal study (in vivo) · rat · 8 results
Robbins RJ · Endocrinology · 1985
In vitro (cells) · rat · 2 results
Soliman AT · Indian journal of endocrinology and metabolism · 2013
Not a test of Cosyntropin alone · 15 results
Daidoh H · Clinical endocrinology · 1995
Not a test of Cosyntropin alone · 12 results
Gonzálbez J · Clinical endocrinology · 2000
Not a test of Cosyntropin alone · 11 results
Hart KA · Journal of veterinary internal medicine · 2007
Not a test of Cosyntropin alone · 11 results
Watterberg KL · The Journal of clinical endocrinology and metabolism · 2005
Not a test of Cosyntropin alone · 10 results
Peechakara S · Endocrine · 2017
Not a test of Cosyntropin alone · 10 results
Abdu TA · The Journal of clinical endocrinology and metabolism · 1999
Not a test of Cosyntropin alone · 8 results
Rosenfield RL · The Journal of clinical endocrinology and metabolism · 1985
Not a test of Cosyntropin alone · 8 results
Elder CJ · The Journal of clinical endocrinology and metabolism · 2020
Not a test of Cosyntropin alone · 8 results
Nagireddi R · Journal of the Endocrine Society · 2020
Not a test of Cosyntropin alone · 6 results
Hart KA · Journal of veterinary internal medicine · 2009
Not a test of Cosyntropin alone · 5 results
Schoeman JP · The Journal of small animal practice · 2000
Not a test of Cosyntropin alone · 5 results
Wagmode NB · Indian journal of endocrinology and metabolism · 2018
Not a test of Cosyntropin alone · 5 results
Rossitto G · Surgery · 2018
Not a test of Cosyntropin alone · 4 results
González-González JG · The Journal of endocrinology · 1998
Not a test of Cosyntropin alone · 4 results
Kemppainen RJ · Journal of the American Animal Hospital Association · 2005
Not a test of Cosyntropin alone · 4 results
Moraes RB · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2012
Not a test of Cosyntropin alone · 4 results
Watson AD · Australian veterinary journal · 1998
Not a test of Cosyntropin alone · 3 results
Wong DM · Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2009
Not a test of Cosyntropin alone · 3 results
Mancillas-Adame LG · International journal of endocrinology · 2022
Not a test of Cosyntropin alone · 3 results
Abu-Ahmad A · Minerva endocrinologica · 2019
Not a test of Cosyntropin alone · 3 results
Merry WH · Surgery · 1994
Not a test of Cosyntropin alone · 2 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA |
| 27 Oct 2026 | dailymed.nlm.nih.gov (opens in a new tab) |
| EU | EMA | No product-specific central EMA authorisation was established. This does not decide national authorisations. | 27 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Banned in sport (WADA S2.2.2) Corticotrophins and their releasing factors are prohibited at all times. | 2026 List | wada-ama.org (opens in a new tab) |
6 safety results for Cosyntropin.
In chemotherapy patients, secondary effects were observed in 5% with tetracosactide and 8% with methylprednisolone, with no significance stated.
Randomized controlled trialn = 102
In cisplatin chemotherapy patients, tetracosactide and dexamethasone with shared background antiemetics did not differ significantly in side effects.
Non-randomized trialn = 33
In the infantile spasms trial, no deaths occurred, including among infants assigned tetracosactide.
Non-randomized trialn = 25
In postpartum patients with PDPH, no side effects of tetracosactide were observed.
Non-randomized trialn = 23
In rheumatic-disease inpatients, local reactions to depot tetracosactrin injection were relatively frequent.
Non-randomized trialn = 12
No hypersensitive asthmatic patient developed allergic reactions to depot-tetracosactrin.
Non-randomized trialn = 9
The doses that these studies used. They are not recommendations.
0·5 mg on alternate daysHuman
1 mgHuman
3 mg on D1 and 2 mg/d on D2 and D3Human
10 mgHuman
1 mgHuman
1 mgHuman
6 of 17 shown
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https:// pepbank.io/ v1/ briefs/ cosyntropinEvidence summary for Cosyntropin: counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 8 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| PainNervous system and cognition | Human: 21 results from 5 studies: 2 increase, 4 decrease, 12 no significant change, 3 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 21 |
| Gastrointestinal protectionGastrointestinal | Human: 7 results from 3 studies: 5 no significant change, 2 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 7 |
| Adrenal FunctionEndocrine and hormones | Human: 6 results from 4 studies: 4 increase, 1 decrease, 1 not reported. Strongest design: Non-randomized trial | Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo) | No results | No results | 7 |
| Adrenal ResponseEndocrine and hormones | Human: 5 results from 1 study: 1 increase, 1 decrease, 3 no significant change. Strongest design: Non-randomized trial | No results | No results | No results | 5 |
| Adverse eventsWhole body | Human: 5 results from 5 studies: 1 no significant change, 4 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 5 |
| Cardiovascular Autonomic FunctionCardiovascular | Human: 5 results from 1 study: 4 decrease, 1 no significant change. Strongest design: Randomized controlled trial | No results | No results | No results | 5 |
| SeizuresNervous system and cognition | Human: 4 results from 2 studies: 1 increase, 3 no significant change. Strongest design: Randomized controlled trial | No results | No results | No results | 4 |
| Bone and jointMusculoskeletal | Human: 3 results from 2 studies: 1 increase, 1 decrease, 1 no significant change. Strongest design: Randomized controlled trial | No results | No results | No results | 3 |
| Receptor activity and mechanismReproductive and sexual health | Human: 2 results from 1 study: 1 increase, 1 no significant change. Strongest design: Non-randomized trial | Animal: 2 results from 1 study: 2 decrease. Strongest design: Animal study (in vivo) | Lab: 2 results from 1 study: 2 decrease. Strongest design: In vitro (cells) | No results | 6 |
| MortalityWhole body | Human: 2 results from 2 studies: 1 decrease, 1 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 2 |
| Stress hormonesEndocrine and hormones | Human: 1 result from 1 study: 1 increase. Strongest design: Randomized controlled trial | Animal: 2 results from 1 study: 2 mixed. Strongest design: Animal study (in vivo) | No results | No results | 3 |
| Blood LossCardiovascular | Human: 1 result from 1 study: 1 decrease. Strongest design: Randomized controlled trial | No results | No results | No results | 1 |
12 outcome groups shown of 24 · 97 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.
Trials by phase
25 registered trials loaded of 27, grouped by phase and shown by status.
Source: ClinicalTrials.gov, data version 308560. Status is the registry status. The counts cover only the loaded trials.